Randomized trial · people
Abaloparatide improved hip geometry vs placebo in ACTIVE-J
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, abaloparatide changed several measures of hip shape and density more than placebo did over 78 weeks, adding detail beyond the density gains already seen in ACTIVE-J.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2023
- Journal
- Arch Osteoporos
What they tested
The team tested whether abaloparatide changes the shape and biomechanical properties of the hip compared with placebo in Japanese people with osteoporosis.
How the study was done
A randomized, placebo-controlled phase 3 trial in Japanese postmenopausal women and men with osteoporosis at high fracture risk. Hip DXA scans (a low-dose X-ray bone scan) from 128 people on 80 μg abaloparatide injected daily and 65 on placebo, a dummy shot, were analyzed from the start up to week 78.

What they found
By week 78, the abaloparatide group's cortical thickness (the hard outer shell of bone) rose 5.3% at the narrow neck, 5.3% at the intertrochanteric region and 2.9% at the upper thigh bone shaft. Section modulus went up 7.4%, 5.4% and 2.4% at those same 3 sites, and buckling ratio fell 5.0% at the intertrochanteric region and 4.1% at the femoral neck. Total volumetric bone mineral density at the total hip rose 2.7% and trabecular (inner, spongy bone) density rose 3.2%. All of these changes were significant compared with placebo.
What it doesn’t show
This is a secondary analysis of hip scans from the trial, so it shows changes in hip shape and density measures, not fewer fractures. It included only Japanese patients, and the placebo group was about half the size of the treated group.
The paper
Sone et al. The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial. Arch Osteoporos. 2023.
The compound
More studies on Abaloparatide
- Abaloparatide, teriparatide beat other drugs on spine BMD in menMeta-analysis · people · 2025
- Abaloparatide: larger hip BMD gains than teriparatide at 24 weeksMeta-analysis · people · 2023
- Abaloparatide raised hip BMD around a virtual hip stem in ACTIVERandomized trial · people · 2024
- Abaloparatide then alendronate: 84% lower vertebral fracture riskRandomized trial · people · 2018
- Abaloparatide: normal bone biopsies after up to 18 months in ACTIVERandomized trial · people · 2017
- Abaloparatide: fewer new vertebral fractures vs placebo in ACTIVERandomized trial · people · 2016
- Every study on Abaloparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.